Business
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026.
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time ","length":78,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026.","length":396,"tagName":"p"},{"type":"image","alt":"Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":115,"url":"https://media.zenfs.com/en/prnewswire.com/8a1e3a48ba1eed38d0965ff99386679c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rr.nFX4JKuLbVXpusTxC5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/8a1e3a48ba1eed38d0965ff99386679c","width":400,"height":115}},"href":"https://mma.prnewswire.com/media/273590/viking_9_15_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, February 11, 2026. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until February 18, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference replay code #3246362. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.","length":824,"tagName":"p"},{"type":"text","content":"About Viking Therapeutics, Inc. ","length":31,"tagName":"p"},{"type":"text","content":"Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of ...